In this article, Patrick Kendall, Scientific Advisor for Artelo Biosciences, outlines why future treatment of cancer anorexia-cachexia syndrome may lie with drugs in development offering a mechanistic approach.
List view / Grid view
Chronic obstructive pulmonary disease (COPD)
Scientists have developed an inhaled treatment for asthma that prevents excess mucus from building up in mice.
Study identifies a promising new compound that can open constricted airways and could be a promising treatment for obstructive lung diseases.
By blocking the lymphotoxin beta receptor signalling pathway, researchers were able to prevent COPD progression and induce a full restoration of lung tissue.
There are heightened levels of abnormal stem cells in the lungs of COPD patients, presenting a drug target that researchers are screening compounds against.
An innovation using artificial intelligence to analyse developing lung cell developments in vitro revealed what promotes them to develop and allowed researchers to create better quality lung tissue models.
Researchers have discovered that genetic variations in the anatomy of the lungs could serve as indicators to help identify people who are particularly at risk for COPD...
An antibody treatment has been found to reduce the rate of flare-ups by nearly 20 percent in patients with a subgroup of treatment-resistant COPD...
Prior to joining CRT-DL, Dr Ryder held positions in pharmaceutical and biotech companies for over 20 years ...
Lung cancer screening is likely to be cost-effective, particularly if it also identifies other tobacco-related conditions in high-risk people, suggests new research.
A new study has found that stem cell therapy can reduce lung inflammation in an animal model of chronic obstructive pulmonary disease (COPD) and cystic fibrosis. Although, still at a pre-clinical stage, these findings have important potential implications for the future treatment of patients.
Sound Pharmaceuticals has been awarded up to $1.6M from Cystic Fibrosis Foundation Therapeutics (CFFT), the non-profit drug discovery and development affiliate of the Cystic Fibrosis Foundation.
SMi’s 13th annual Asthma & COPD conference returns to London on the 29 and 30 March 2017...
MRC Technology, AstraZeneca, Asthma UK and British Lung Foundation to collaborate on respiratory disease research
1 September 2016 | By Niamh Louise Marriott, Digital Content Producer
A collaboration to investigate the link between epigenetics and respiratory disease and to find new drug treatments involves...